Beijing BIOOCUS Biotech Ltd. is a leading CAR-T company specializing in the development and commercialization of innovative cellular immunotherapy products. Our flagship product, BIOCAR-TCR/CD19, is a novel CAR-T therapy designed to target and eliminate cancer cells in patients with relapsed or refractory B-cell malignancies, With a strong focus on research and development, Beijing BIOOCUS Biotech Ltd. is committed to advancing the field of CAR-T therapy and bringing groundbreaking treatments to patients in need. Our team of renowned scientists and medical experts work tirelessly to optimize the safety and efficacy of BIOCAR-TCR/CD19, ensuring that it meets the highest standards of quality and performance, Through strategic partnerships and collaborations, we aim to accelerate the global expansion of BIOCAR-TCR/CD19 and make this life-saving therapy accessible to patients around the world. At Beijing BIOOCUS Biotech Ltd., we are dedicated to revolutionizing cancer treatment and improving the lives of patients through our innovative CAR-T products
Please feel free to give your inquiry in the form below We will reply you in 24 hours